{"DataElement":{"publicId":"6662366","version":"1","preferredName":"Preparative Regimen Administration Type","preferredDefinition":"A description of the recipient's conditioning regimen.","longName":"2719190v1.0:6662352v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2719190","version":"1","preferredName":"Preparative Regimen Administration","preferredDefinition":"The chemotherapy and/or radiation given to blood, marrow or cord blood transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","longName":"PREP_REG_ADMN","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2685191","version":"1","preferredName":"Preparative Regimen","preferredDefinition":"The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur.","longName":"C61155","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Preparative Regimen","conceptCode":"C61155","definition":"The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B97F286-866B-5609-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-10-03","modifiedBy":"ONEDATA","dateModified":"2007-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2320521","version":"1","preferredName":"Administration","preferredDefinition":"The act of administration.","longName":"C25409","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-053F-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"434EACD2-214D-1396-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-31","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-01-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".12/20/13mn-updated def of prep reg. semantically the same - no versioning needed.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6662352","version":"1","preferredName":"Preparative Regimen Type","preferredDefinition":"The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur._Something distinguishable as an identifiable class based on common qualities.","longName":"6662352v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"None of the above","valueDescription":"None of the Above","ValueMeaning":{"publicId":"5913672","version":"1","preferredName":"None of the Above","longName":"5913672","preferredDefinition":"None of the choices above are suitable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None of the Above","conceptCode":"C133298","definition":"None of the choices above are suitable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5499ACEF-10D1-1155-E053-F662850A3955","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-07-18","modifiedBy":"KUMMEROA","dateModified":"2022-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83733984-841E-5B02-E053-F662850A9444","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"ONEDATA","dateModified":"2019-03-06","deletedIndicator":"No"},{"value":"Fludarabine and myeloablative dose total body irradiation","valueDescription":"Fludarabine And Myeloablative Chemotherapy Dose Total-Body Irradiation Transplant Conditioning","ValueMeaning":{"publicId":"6662353","version":"1","preferredName":"Fludarabine And Myeloablative Chemotherapy Dose Total-Body Irradiation Transplant Conditioning","longName":"6662353","preferredDefinition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The administration of high-dose chemotherapy, with or without total body irradiation, to eradicate the underlying disease and/or ablate the immune system of the patient.: A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.: A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.: Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Myeloablative Chemotherapy","conceptCode":"C16231","definition":"The administration of high-dose chemotherapy, with or without total body irradiation, to eradicate the underlying disease and/or ablate the immune system of the patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Transplant Conditioning","conceptCode":"C64468","definition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83733984-842F-5B02-E053-F662850A9444","latestVersionIndicator":"Yes","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"ONEDATA","dateModified":"2019-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83733984-8448-5B02-E053-F662850A9444","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"ONEDATA","dateModified":"2019-03-06","deletedIndicator":"No"},{"value":"Fludarabine and busulfan","valueDescription":"Fludarabine And Busulfan Transplant Conditioning","ValueMeaning":{"publicId":"6662354","version":"1","preferredName":"Fludarabine And Busulfan Transplant Conditioning","longName":"6662354","preferredDefinition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04): Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Transplant Conditioning","conceptCode":"C64468","definition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83733984-8457-5B02-E053-F662850A9444","latestVersionIndicator":"Yes","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"ONEDATA","dateModified":"2019-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83733984-8470-5B02-E053-F662850A9444","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"ONEDATA","dateModified":"2019-03-06","deletedIndicator":"No"},{"value":"Fludarabine and melphalan +/- total body irradiation","valueDescription":"Fludarabine And Melphalan With Or Without Total-Body Irradiation Transplant Conditioning","ValueMeaning":{"publicId":"6662355","version":"1","preferredName":"Fludarabine And Melphalan With Or Without Total-Body Irradiation Transplant Conditioning","longName":"6662355","preferredDefinition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.: Used to indicate the presence of something or someone.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Used to indicate the absence or lack of something or someone.: A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.: Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Transplant Conditioning","conceptCode":"C64468","definition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83733984-8483-5B02-E053-F662850A9444","latestVersionIndicator":"Yes","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"ONEDATA","dateModified":"2019-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83733984-849C-5B02-E053-F662850A9444","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"ONEDATA","dateModified":"2019-03-06","deletedIndicator":"No"},{"value":"Cyclophosphamide and total body irradiation +/- fludarabine","valueDescription":"Cyclophosphamide And Total-Body Irradiation With Or Without Fludarabine Transplant Conditioning","ValueMeaning":{"publicId":"6662357","version":"1","preferredName":"Cyclophosphamide And Total-Body Irradiation With Or Without Fludarabine Transplant Conditioning","longName":"6662357","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.: Used to indicate the presence of something or someone.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Used to indicate the absence or lack of something or someone.: A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04): Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Transplant Conditioning","conceptCode":"C64468","definition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83733984-84DA-5B02-E053-F662850A9444","latestVersionIndicator":"Yes","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"ONEDATA","dateModified":"2019-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83733984-84F3-5B02-E053-F662850A9444","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"ONEDATA","dateModified":"2019-03-06","deletedIndicator":"No"},{"value":"Cyclophosphamide and busulfan +/- total body irradiation","valueDescription":"Cyclophosphamide And Busulfan With Or Without Total-Body Irradiation Transplant Conditioning","ValueMeaning":{"publicId":"6676274","version":"1","preferredName":"Cyclophosphamide And Busulfan With Or Without Total-Body Irradiation Transplant Conditioning","longName":"6676274","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04): Used to indicate the presence of something or someone.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Used to indicate the absence or lack of something or someone.: A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.: Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Transplant Conditioning","conceptCode":"C64468","definition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"842790BB-E5A3-4415-E053-F662850AF87F","latestVersionIndicator":"Yes","beginDate":"2019-03-15","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-15","modifiedBy":"ONEDATA","dateModified":"2019-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"842790BB-E5BC-4415-E053-F662850AF87F","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-15","modifiedBy":"ONEDATA","dateModified":"2019-03-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2486891","version":"1","preferredName":"Preparative Regimen Type","preferredDefinition":"The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill\r\ndiseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not\r\noccur.:Type; a subdivision of a particular kind of thing.","longName":"C61155:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Preparative Regimen","conceptCode":"C61155","definition":"The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"165D7B9B-8B53-1E50-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"ONEDATA","dateModified":"2006-06-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83733984-8408-5B02-E053-F662850A9444","latestVersionIndicator":"Yes","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"KUMMEROA","dateModified":"2019-12-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the recipient's cond","type":"Preferred Question Text","description":"What was the recipient's conditioning regimen?","url":null,"context":"NHLBI"},{"name":"Specify the recipient's conditioning regimen","type":"Application Standard Question Text","description":"Specify the recipient's conditioning regimen","url":null,"context":"NHLBI"},{"name":"Specify the recipient's conditioning regimen","type":"Alternate Question Text","description":"Specify the recipient's conditioning regimen","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83734108-680C-71BF-E053-F662850A7602","latestVersionIndicator":"Yes","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"KUMMEROA","dateModified":"2019-12-31","changeDescription":". System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}